Latest news with #Dr.Reddy
Economic Times
5 days ago
- Business
- Economic Times
Buy, Sell or Hold: Antique maintains Hold on Infosys; Nuvama maintains Buy on Dr Reddy's Laboratories
Live Events Antique on Infosys: Hold | Target price: Rs 1,750 Nuvama on Dr. Reddy's Laboratories: Buy | Target: Rs 1,486 | LTP: Rs 1,247 | Upside: 19% Motilal Oswal on Tata Consumer Products: Buy | Target: Rs 1,270 (earlier Rs 1,300) | LTP: Rs 1,062 | Upside: 19% (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Brokerages have shared their latest views on key Indian stocks, highlighting a mix of steady performance, emerging growth drivers, and sector-specific Antique has maintained a cautious stance on Infosys , citing margin pressures and limited changes in organic growth guidance, Nuvama remains optimistic about Dr. Reddy's Laboratories, driven by pipeline progress and a strong outlook for its CDMO Motilal Oswal has reiterated its bullish view on Tata Consumer Products , expecting margin expansion and synergies from recent acquisitions to support earnings a summary of their recommendations and insights for the next 12 have compiled key brokerage recommendations from ET Now and other sources:Antique has maintained a 'Hold' rating on Infosys with a target price of Rs 1,750. While the company delivered a strong quarterly performance, its organic growth guidance remains largely reported a robust total contract value (TCV) of $3.8 billion, reflecting solid deal bookings. However, discretionary spending remains weak, and the company continues to face margin headwinds. As a result, EPS estimates for FY26 and FY27 remain has maintained a 'Buy' rating on Dr. Reddy's Laboratories with a target price of Rs 1,486, implying a 19% upside from the last traded price of Rs 1, the company's Q1 performance was below expectations, new growth drivers are emerging. Semaglutide's progress in Canada remains on track, and a US filing for Abatacept is expected—both positive CDMO business is expected to contribute $100 million in FY26, with a target of reaching $300 million by FY30—a significant upside the company has reaffirmed its 25% margin guidance, backed by ongoing cost optimisation Oswal has reiterated its 'Buy' rating on Tata Consumer Products, revising the target price slightly to Rs 1,270 from Rs 1,300, indicating a 19% upside from the current price of Rs 1, brokerage expects moderating tea prices to support margin expansion starting Q2FY26. Consolidated margins are likely to improve, led by the tea business, while the international segment is expected to sustain its from the integration of Capital Foods and Organic India are also expected to boost the domestic food segment. The company has guided for ~16% EBITDA margin by has accordingly raised its EBITDA estimates for FY26 and FY27 by 7% and 3%, respectively.
Time of India
5 days ago
- Business
- Time of India
Buy, Sell or Hold: Antique maintains Hold on Infosys; Nuvama maintains Buy on Dr Reddy's Laboratories
Brokerages have shared their latest views on key Indian stocks, highlighting a mix of steady performance, emerging growth drivers, and sector-specific tailwinds. While Antique has maintained a cautious stance on Infosys , citing margin pressures and limited changes in organic growth guidance, Nuvama remains optimistic about Dr. Reddy's Laboratories, driven by pipeline progress and a strong outlook for its CDMO business. Explore courses from Top Institutes in Please select course: Select a Course Category Healthcare Degree Cybersecurity CXO Digital Marketing PGDM MBA Public Policy MCA Data Science Design Thinking Leadership others Data Analytics Others Operations Management Artificial Intelligence Project Management Product Management Data Science healthcare Technology Finance Management Skills you'll gain: Financial Analysis in Healthcare Financial Management & Investing Strategic Management in Healthcare Process Design & Analysis Duration: 12 Weeks Indian School of Business Certificate Program in Healthcare Management Starts on Jun 13, 2024 Get Details Meanwhile, Motilal Oswal has reiterated its bullish view on Tata Consumer Products , expecting margin expansion and synergies from recent acquisitions to support earnings growth. Here's a summary of their recommendations and insights for the next 12 months. We have compiled key brokerage recommendations from ET Now and other sources: Antique on Infosys: Hold | Target price: Rs 1,750 Antique has maintained a 'Hold' rating on Infosys with a target price of Rs 1,750. While the company delivered a strong quarterly performance, its organic growth guidance remains largely unchanged. Infosys reported a robust total contract value (TCV) of $3.8 billion, reflecting solid deal bookings. However, discretionary spending remains weak, and the company continues to face margin headwinds. As a result, EPS estimates for FY26 and FY27 remain unchanged. Nuvama on Dr. Reddy's Laboratories: Buy | Target: Rs 1,486 | LTP: Rs 1,247 | Upside: 19% Nuvama has maintained a 'Buy' rating on Dr. Reddy's Laboratories with a target price of Rs 1,486, implying a 19% upside from the last traded price of Rs 1,247. Though the company's Q1 performance was below expectations, new growth drivers are emerging. Semaglutide's progress in Canada remains on track, and a US filing for Abatacept is expected—both positive developments. The CDMO business is expected to contribute $100 million in FY26, with a target of reaching $300 million by FY30—a significant upside surprise. Additionally, the company has reaffirmed its 25% margin guidance, backed by ongoing cost optimisation efforts. Motilal Oswal on Tata Consumer Products: Buy | Target: Rs 1,270 (earlier Rs 1,300) | LTP: Rs 1,062 | Upside: 19% Motilal Oswal has reiterated its 'Buy' rating on Tata Consumer Products, revising the target price slightly to Rs 1,270 from Rs 1,300, indicating a 19% upside from the current price of Rs 1,062. The brokerage expects moderating tea prices to support margin expansion starting Q2FY26. Consolidated margins are likely to improve, led by the tea business, while the international segment is expected to sustain its growth. Synergies from the integration of Capital Foods and Organic India are also expected to boost the domestic food segment. The company has guided for ~16% EBITDA margin by Q3FY26. Motilal has accordingly raised its EBITDA estimates for FY26 and FY27 by 7% and 3%, respectively. ( Disclaimer : Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of The Economic Times)
Time of India
5 days ago
- Business
- Time of India
Delhi HC seeks Dr Reddy's reply in Novo patent dispute
Synopsis The Delhi High Court has directed Dr. Reddy's Labs to respond to Novo Nordisk's injunction petition concerning its weight-loss drug, semaglutide (Wegovy). Novo Nordisk alleges patent infringement, prompting the court's action. An IP expert suggests Dr. Reddy's Labs may need to justify its semaglutide exports, as Novo Nordisk's patent is set to expire in March of next year.
The Hindu
5 days ago
- Business
- The Hindu
Dr. Reddy's Q1 net inches up amid decline in generics sales to U.S.
Generic drugmaker Dr. Reddy's Laboratories' consolidated net profit for the June quarter increased marginally to ₹1,409.9 crore from Rs.1,392.4 crore year earlier as revenue from the all important U.S. market declined amid increased price erosion in certain key products. The net profit came on a more than 11% increase in total revenue from operations to ₹.8,572.1 crore (₹.7,696.1 crore), the results prepared as per Indian Accounting Standards (Ind AS) showed. Pricing pressure on cancer drug Lenalidomide is expected to intensify in the U.S. generics market, according to co-chairman and MD G.V. Prasad. He said this reaffirming the company's focus on strengthening the base business by delivery of our pipeline assets, improving overall productivity and business development.' On segment revenue, the company said global generics contributed ₹7,573.2 crore (₹.6,892.9 crore), while share of Pharmaceutical Services and Active Ingredients declined to ₹987.4 crore (₹1,047.2 crore). In a release, on the results prepared as per International Financial Reporting Standards (IFRS), Dr. Reddy's said revenue from the North America generics market at ₹3,410 crore was 11% lower a decline YoY of and 4% QoQ. The decline was primarily due to increased price erosion in certain key products, including Lenalidomide. Revenue from generics sales in Europe, India and Emerging Markets were higher year on year. The company's shares closed less than 1% higher at ₹1,247.55 each on the BSE.
Hans India
5 days ago
- Business
- Hans India
Dr. Reddy's Laboratories' net profit slumps 11 pc to Rs 14,09 crore sequentially in Q1
Mumbai: Dr. Reddy's Laboratories' net profit stood at Rs 1,409.6 crore in the first quarter of the current fiscal (Q1 FY26), down 11 per cent sequentially, the company said in an exchange filing on Wednesday. The company had reported a consolidated profit of Rs 1,587.3 crore in the preceding quarter (Q4 FY25). However, the profit of the Hyderabad-based firm saw a marginal jump of over a per cent on year-on-year (YoY) from Rs 1,392 crore in the same quarter a year ago, according to the filing. Meanwhile, Dr. Reddy's Labs revenue stood at Rs 8,545.2 crore in the quarter under review, up around Rs 40 crore sequentially from Rs 8,506 crore, and Rs 872.5 crore year-on-year (YoY) from Rs 7,672.7 crore. The pharmaceutical company saw a jump of Rs 153 crore in its total operating expenses this quarter QoQ, leading to a decline in its net profit. The company reported total operating expenses of Rs 3,115.2 crore in Q1 FY26 against Rs 2,961.6 crore in Q4 FY25. "We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio. The pricing pressure on Lenalidomide is expected to intensify in the U.S. generics market," said GV Prasad, Co-Chairman and MD. "We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development," Prasad added. Meanwhile, the company has expanded partnership with Alvotech to co-develop, manufacture and co-commercialise pembrolizumab, a biosimilar candidate, this quarter, as per the filing. It has also launched Sensimune in India, an immunotherapy product for house dust mite-induced allergies. The shares of the company closed in positive territory on Wednesday. The stock settled at Rs 1,248.0, up 0.65 per cent. Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad.
